Cytori Therapeutics (CYTX) Tops Q1 EPS by 2c, Miss on Revenues

Cytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.57 million.

Selected Key Recent Highlights:

• Received U.S. FDA approval for thermal burn IDE pilot trial application related to ongoing BARDA contract.
• Received U.S. FDA orphan drug designation for cryopreserved or centrally processed HabeoTM for treatment of hand manifestations of systemic scleroderma.
• Received U.S. Small Business Designation and related fee reductions.

Q1 2017 Financial Performance

• Q1 2017 operating cash burn was $4.8 million, compared to $5.1 million for Q1 2016.
• Q1 2017 total revenues were $1.6 million, compared to $2.9 million in Q1 2016.
• Cash and debt principal balances at March 31, 2017 were approximately $6.3 million and $15.9 million, respectively.
• Q1 2017 adjusted net loss was $5.9 million or $0.26 per share, compared to a net loss of $5.3 million or $0.41 per share for Q1 2016.
• Q1 2017 GAAP net loss was $7.5 million or $0.33 per share, compared to a net loss of $5.3 million or $0.41 per share for Q1 2016.

For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c